Advanced CLD with S-CHOice®: Higher Productivity with Transposase Technology and Improved ADCC with S-AfuCHO™

This webcast features: Janet Lee, director, cell line development, Samsung Biologics.

The increasing complexity of biopharmaceutical molecules is driving innovation in cell line development (CLD) to enhance productivity and functionality. To address these evolving demands, Samsung Biologics has developed two advanced platforms: S-CHOice® and S-AfuCHO™.

The S-CHOice® platform, powered by transposase technology, tackles common CLD challenges such as low protein expression, multi-chain molecule complexity, and clonal instability. It ensures efficient and scalable biologics production while meeting stringent timelines and reducing product impurities.

The S-AfuCHO™ platform features an afucosylated CHO cell line engineered through FUT8 knockout technology. By removing core fucose from the antibody’s Fc region, it enhances binding affinity to FcγIIIa receptors, significantly improving antibody-dependent cellular cytotoxicity (ADCC) functionality.

Join this webinar to learn how these platforms optimize CLD performance and support efficient, reliable production of complex biologics.

Key Takeaways:

Register or Login and hit Watch on Demand to view the recorded webcast now.